{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":17,"n_cols":5,"rows_kept":17,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[9,2,9,3],[10,2,10,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910461307503321"]
[null,null,"Titolo",null,"Drug resistant neoplasms [[electronic resource] /] / Ethan G. Verrite, editor"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Science Publishers, c2009"]
[null,null,"ISBN",null,"1-61324-474-6"]
[null,null,"Descrizione fisica",null,"1 online resource (269 p.)"]
[null,null,"Collana",null,"Cancer etiology, diagnosis and treatments series"]
[null,null,"Disciplina",null,"616.99/4061"]
[null,null,"Soggetti",null,"Drug resistance in cancer cells"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Therapeutic implications of the intrinsic and acquired resistance of cancer stem/progenitor cells in inefficacy of current cancer treatments and disease relapse / Murielle Mimeault and Surinder K. Batra -- Role of O6-methyl guanine-DNA methyl transferase and the effect of O6-benzylguanine in cancer chemotherapy / Jun Murakami ... [et al.] -- The role of tumoural micro-environment and its vasculature on chemotherapy drug resistance: the potential for it's modulation to achieve therapeutic gain / A. Weickhardt and M. Michael -- Inherent and microenvironment-mediated mechanisms of drug resistance / Malathy P.V Shekhar -- Studies on the mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor gefitinib in NSCLC cell lines: evidence that ligand-induced endocytosis of EGFR via the early/late endocytic pathway is associated with gefitinib sensitivity of NSCLC cell line / Yukio Nishimura -- Mechanisms of resistance to EGF receptor-tyrosine kinase inhibitor in NSCLC cell lines: gefitinib sensitivity is closely correlated with ligand-induced endocytosis of phosphorylated EGF receptor / Yukio Nishimura, Kiyoko Yoshioka and Kazuyuki Itoh -- Targeting adverse features of hormone-resistant breast cancer / Stephen Hiscox ... [et al.] -- Systematic analysis of patterns of cross resistance between anticancer agents / Britta Stordal and Ross Davey -- Molecular structure and energy: clinical importance in drug resistant neoplasms / Viroj Wiwanitkit -- Treating drug resistant malignancy / Viroj Wiwanitkit -- Overcoming ovarian cancer drug resistance with phytochemicals and other compounds / Marion M. Chan and Dunne Fong -- New research communications on cancer drug resistance, assessment of cancer drug resistance with nuclear medicine images / "]
[{"$nulls":4},"Seigo Kinuya."]
[null,null,null,"Sommario/riassunto","\"One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Frequently, resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells. Studies on the mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and its implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field\"--Publisher's description."]